{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:29:30Z","timestamp":1793730570500,"version":"4.6.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Merkel cell carcinoma (MCC) is a rare, aggressive neurocutaneous malignancy associated with ultraviolet damage, immunosuppression, and Merkel cell polyoma virus infection. Periocular MCC is uncommon but has high rates of local recurrence and metastasis and presents unique therapeutic challenges due to functional and cosmetic considerations. Immune checkpoint inhibitor (ICI) therapy has shown efficacy in systemic MCC; however, evidence for periocular use is limited to small case series and reports without consolidated evidence or consensus. Thus, this study summarizes and evaluates the effectiveness and safety of ICIs for periocular MCC. A systematic literature search across PubMed, Embase, and Web of Science was conducted according to PRISMA guidelines. Randomized and nonrandomized studies, case series, and case reports in English describing ICI use for periocular MCC were included. Non-human studies, non-periocular MCC, and reports without ICI treatment were excluded. Extracted data included patient demographics, tumor characteristics, treatment regimen, and patient outcomes. Seven studies reporting ten patients were included. Treatment regimens consisted of pembrolizumab (n = 6) and avelumab (n = 3), or both medications (n = 1). At a mean follow-up of 11.4 \u00b1 9.0 months, nine patients had complete response (90%); only one patient developed subsequent distant progression despite local response. Patients with both localized periocular disease and metastatic involvement demonstrated favorable responses to ICI. Adverse effects were infrequent and typically mild; only one patient discontinued therapy due to adverse effects. ICIs may be an effective and well-tolerated treatment for local and advanced periocular MCC; however, larger, prospective studies are needed.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3208_25","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:00:20Z","timestamp":1779858020000},"page":"821-827","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitor therapy for treatment of periocular Merkel cell carcinoma: A systematic review of clinical outcomes and safety"],"prefix":"10.4103","volume":"74","author":[{"given":"Gillian A.","family":"Folk","sequence":"first","affiliation":[{"name":"University of California San Diego School of Medicine, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Lee","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa K.","family":"Shoji","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel cell carcinoma","volume":"3","author":"Becker","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.survophthal.2019.03.002","article-title":"Merkel cell carcinoma of the eyelid: A review","volume":"64","author":"North","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2007.11.020","article-title":"Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: The \u201cAEIOU\u201d features","volume":"58","author":"Heath","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/SJOPT.SJOPT_55_21","article-title":"Merkel cell carcinoma of the eyelid and periocular region: A review","volume":"35","author":"Walsh","year":"2022","journal-title":"Saudi J Ophthalmol"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/IOP.0000000000000153","article-title":"Correlation of American Joint Committee on Cancer T Category for eyelid carcinoma with outcomes in patients with periocular Merkel cell carcinoma","volume":"30","author":"Sniegowski","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2217\/fon-2017-0072","article-title":"Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma","volume":"13","author":"Nghiem","year":"2017","journal-title":"Future Oncol"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/cancers6021128","article-title":"Merkel cell carcinoma of the eyelid and periocular region","volume":"6","author":"Merritt","year":"2014","journal-title":"Cancers"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.2147\/OPTH.S263291","article-title":"Ocular complications after radiation therapy: An observational study","volume":"14","author":"Nuzzi","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/cup.13910","article-title":"Merkel cell carcinoma: A review","volume":"48","author":"Walsh","year":"2021","journal-title":"J Cutan Pathol"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: Clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO-24-02138","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma: A nonrandomized, open-label, international, multicenter phase I\/II study","volume":"43","author":"Bhatia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"R13-20261103","first-page":"545","article-title":"A phase 2 study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC) (POD1UM-201)","volume":"9","author":"Grignani","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/IOP.0000000000001078","article-title":"Biopsy-proven metastatic Merkel cell carcinoma to the orbit: Case report and review of literature","volume":"34","author":"Cugley","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13256-021-02690-z","article-title":"Cerebral metastasis of Merkel cell carcinoma following resection with negative margins and adjuvant external beam radiation: A case report","volume":"15","author":"Grubb","year":"2021","journal-title":"J Med Case Rep"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ophtha.2024.08.004","article-title":"Immune checkpoint inhibitor therapy for periocular Merkel cell carcinoma","volume":"132","author":"Hohlbein","year":"2025","journal-title":"Ophthalmology"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/1750743X.2025.2554566","article-title":"Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis","volume":"17","author":"Arnold","year":"2025","journal-title":"Immunotherapy"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jdcr.2024.03.027","article-title":"Merkel cell carcinoma in the context of follicular lymphoma treated with radiation and avelumab","volume":"53","author":"Nishizawa","year":"2024","journal-title":"JAAD Case Rep"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"adv00237","DOI":"10.2340\/00015555-3593","article-title":"Effectiveness of combined anti-programmed death-ligand 1 therapy and radiotherapy for metastatic Merkel cell carcinoma: Two case reports","volume":"100","author":"Tsunoda","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.jcjo.2023.10.019","article-title":"Immune checkpoint inhibition therapy as first-line treatment for localized eyelid Merkel cell carcinoma in a nonsurgical candidate","volume":"59","author":"Zhan","year":"2024","journal-title":"Can J Ophthalmol"},{"key":"R21-20261103","first-page":"442","article-title":"Clinicopathologic features and prognostic factors of malignant eyelid tumors","volume":"6","author":"Wang","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/cancers12040888","article-title":"Tumor ulceration, reduced infiltration of CD8-lymphocytes, high neutrophil-to-CD8-lymphocyte ratio and absence of MC virus are negative prognostic markers for patients with Merkel cell carcinoma","volume":"12","author":"Naseri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/cup.12973","article-title":"PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma","volume":"44","author":"Mitteldorf","year":"2017","journal-title":"J Cutan Pathol"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"103461","DOI":"10.1016\/j.esmoop.2024.103461","article-title":"First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study","volume":"9","author":"D\u2019Angelo","year":"2024","journal-title":"ESMO Open"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"R28-20261103","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"R30-20261103","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-18-4159","article-title":"The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy","volume":"25","author":"Knepper","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R31-20261103","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/cam4.815","article-title":"Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma","volume":"5","author":"Iyer","year":"2016","journal-title":"Cancer Med"},{"key":"R32-20261103","doi-asserted-by":"crossref","DOI":"10.4081\/dr.2025.10457","article-title":"Rate of growth of Merkel cell carcinoma: A unique photographic evidence","author":"Bearzi","year":"2025","journal-title":"Dermatol Rep"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3208_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:01:36Z","timestamp":1793728896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3208_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3208_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"2025-12-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}